Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rivaroxaban tablet

A technology for rivaroxaban and tablets, which is applied in the field of medicine, can solve the problems of failure to provide rivaroxaban tablets and poor dissolution of tablets, and achieve the effects of fast dissolution, good stability and simple process

Active Publication Date: 2015-06-03
SHANDONG NEWTIME PHARMA
View PDF11 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tablets prepared by the invention have poor dissolution rate
[0015] In the prior art, a rivaroxaban tablet with rapid dissolution in vitro, good stability and simple preparation process has not been provided.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rivaroxaban tablet
  • Rivaroxaban tablet
  • Rivaroxaban tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] prescription:

[0028]

[0029]

[0030] Preparation Process:

[0031] Dissolve rivaroxaban in diethylene glycol monoethyl ether, add hydroxypropyl cellulose, stir to dissolve, then add the prescribed amount of fumed silica for adsorption, and then mix with lactose, sodium carboxymethyl starch, stearin Sodium fumarate is mixed evenly and compressed by direct compression technology.

Embodiment 2

[0033] prescription:

[0034]

[0035] Preparation Process:

[0036] Dissolve rivaroxaban in diethylene glycol monoethyl ether, add hydroxypropyl cellulose, stir to dissolve, then add the prescribed amount of fumed silica for adsorption, and then mix with microcrystalline cellulose and crospovidone , Magnesium stearate mixed uniformly, compressed by direct compression process.

Embodiment 3

[0038] prescription:

[0039]

[0040]

[0041] Preparation Process:

[0042] Dissolve rivaroxaban in diethylene glycol monoethyl ether, add hydroxypropyl cellulose, stir to dissolve, then add the prescribed amount of fumed silica for adsorption, and then mix with mannitol, starch, and cross-linked carboxymethyl Sodium cellulose, silicon dioxide and magnesium stearate are uniformly mixed and compressed by direct compression technology.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
diameteraaaaaaaaaa
weight ratioaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of drugs and in particular relates to a rivaroxaban tablet. The rivaroxaban tablet contains rivaroxaban, hydroxypropyl cellulose and fumed silica and is prepared by dissolving rivaroxaban and hydroxypropyl cellulose in diethylene glycol monoethyl ether, adding fumed silica for adsorption, then mixing the materials with pharmaceutically acceptable auxiliary materials uniformly and pressing the mixture by adopting a direct tabletting process. Compared with the prior art, the rivaroxaban tablet is high in drug dissolution speed and simple in process and dispenses with addition of surfactants and micronization treatment.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a rivaroxaban tablet. Background technique [0002] Rivaroxaban is the world's first oral direct factor Xa inhibitor jointly developed by Bayer Pharmaceuticals and Johnson & Johnson. It was approved for marketing in Canada and the European Union on September 15, 2008 and October 1, 2008. The trade name is for Xarelto. Rivaroxaban is a low molecular weight oral anticoagulant with high selectivity and direct inhibitory effect on factor Xa, which is used for the prevention and / or treatment of various embolic diseases. Chemical name: 5-chloro-nitrogen-((5S)-2-oxo-3-[-4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl- 2-thiophene-carboxamide, molecular formula: C 19 h 18 ClN 3 o 5 S, molecular weight: 435.89, structural formula as follows: [0003] [0004] Rivaroxaban is soluble in dimethyl sulfoxide and practically insoluble in methanol or water. Rivaroxaban...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/5377A61K47/04A61K47/38A61P7/02
Inventor 张贵民陈小伟高西蒙
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com